Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 45, 2016, Pages 74303-74313

  Ha, Yeonjung ^a,b   Lee, Danbi ^a   Shim, Ju Hyun ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Park, Sook Ryun ^a   Ryu, Min Hee ^a   Ryoo, Baek Yeol ^a   Kang, Yoon Koo ^a   Kim, Kang Mo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Hepatocellular carcinoma; Overall survival; Portal vein invasion; Sorafenib; Transarterial chemoembolization

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PORTAL VEIN INVASION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TUMOR INVASION; VOMITING; ANALOGS AND DERIVATIVES; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84995810964     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11030     Document Type: Article

References (27)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine. 2008; 359:378-390.
2. Choi JY. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. Oncology. 2011; 81 Suppl 1:141-147.
3. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS and Suh DJ. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. Journal of gastroenterology and hepatology. 2009; 24:806-814.
4. Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, Li Y, Fan D and Han G. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia-Pacific journal of clinical oncology. 2013; 9:357-364.
5. Xue TC, Xie XY, Zhang L, Yin X, Zhang BH and Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a metaanalysis. BMC gastroenterology. 2013; 13:60.
6. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L and Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. The oncologist. 2012; 17:359-366.
7. Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B and Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World journal of hepatology. 2013; 5:364-371.
8. Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S and Yang Z. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PloS one. 2014; 9:e96620.
9. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX, Luo JJ, Liu LX, Liu R and Qian S. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC cancer. 2012; 12:263.
10. Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu KC, Xia JL, Fan DM and Han GH. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. Journal of digestive diseases. 2013; 14:181-190.
11. Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM and Nam BH. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. Journal of hepatology. 2012; 56:1336-1342.
12. Hsiao W-D, Peng C-Y, Chuang P-H, Lai H-C, Cheng K-S, Chou J-W, Chen Y-Y, Yu C-J, Feng C-L and Su W-P. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC gastroenterology. 2016; 16:1.
13. Geschwind J-F, Kudo M, Marrero JA, Venook AP, Chen X-P, Bronowicki J-P, Dagher L, Furuse J, Ladrón de Guevara L and Papandreou C. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 2016:150667.
14. Zhao Y, Li H, Bai W, Liu J, Lv W, Sahu S, Guan S, Qin X, Wang W and Ren W. Early SorafenibRelated Adverse Events Predict Therapy Response of TACE plus Sorafenib: A Multicenter Clinical Study of 606 HCC Patients. International journal of cancer. 2016.
15. Yao X, Yan D, Zeng H, Liu D and Li H. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. Journal of surgical oncology. 2016; 113:672-677.
16. Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M and Shan H. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study. Radiology. 2014; 272:284-293.
17. Wang G, Liu Y, Zhou S-f, Qiu P, Xu L, Wen P, Wen J and Xiao X. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatology international. 2016; 10:501-510.
18. HuU, Jia L, Liu H, Zhang K and Guo G. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 2016; 20:64-74.
19. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The lancet oncology. 2009; 10:25-34.
20. Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O and Mathurin P. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Alimentary pharmacology & therapeutics. 2011; 34:1193-1201.
21. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM and Kang YK. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer chemotherapy and pharmacology. 2011; 68:1285-1290.
22. Schutte K, Zimmermann L, Bornschein J, Csepregi A, Ruhl R, Ricke J and Malfertheiner P. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion. 2011; 83:275-282.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT and Christian MC. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute. 2000; 92:205-216.
24. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S and Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009; 45:228-247.
25. Lencioni R and Llovet JM. (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease, pp. 52-60.
26. Ha Y, Lee JB, Shim JH, Kim KM, Lim YS, Yoon HK, Shin YM and Lee HC. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. European radiology. 2016.
27. National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0and v.4.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.